| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | MS-275 | gCSI | pan-cancer | AAC | 0.041 | 0.4 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.026 | 0.4 |
| mRNA | AP-24534 | FIMM | pan-cancer | AAC | 0.13 | 0.4 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.028 | 0.4 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.029 | 0.4 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.14 | 0.4 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | 0.04 | 0.4 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.026 | 0.4 |